Literature DB >> 14732919

Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.

Karin G Hermans1, Dirk C van Alewijk, Joris A Veltman, Wytske van Weerden, Ad Geurts van Kessel, Jan Trapman.   

Abstract

We examined 11 prostate cancer xenografts and 4 cell lines for chromosome 10 alterations. Conventional comparative genomic hybridization (CGH) and array-based CGH revealed a pattern of loss of distal 10p, gain of proximal 10p and 10q, and loss of distal 10q. In addition, array CGH identified 2 high-level amplifications in the cell line PC3, homozygous deletions of PTEN in PC3 and in the xenografts PCEW, PC133, and PC324, and small single- or double-copy deletions around PTEN in PCEW, PC82, PC324, PC346, and LNCaP. Allelotype analysis confirmed all 10p losses, 5 of 6 large 10q losses, the homozygous deletions, and the small regions of one copy loss. MXI1, DMBT1, and KLF6 were excluded as important tumor-suppressor genes. The sizes of homozygous deletions around PTEN ranged from 1.2 Mbp (PC133) to <30 kbp (PTEN exon 5 in PC295). The regions of small single- or double-copy loss around PTEN were all less than 4.5 Mbp. The loss of 1 or 2 copies of PTEN was always accompanied by loss of the distal flanking gene FLJ11218 and, in most cases, by loss of the proximal flanking genes MINPP1, PAPSS2, and FLJ14600. Furthermore, differential expression was detected for FLJ11218 and PAPSS2. Complete deletion or inactivating mutation of PAPSS2 was found in at least 3 samples. In addition to 4 homozygous deletions, 1 missense mutation was detected in FLJ11218. In conclusion, our data provide evidence that loss of a small region around PTEN is the major chromosome 10 alteration in prostate cancer xenografts and cell lines. In some of the samples, PTEN inactivation was accompanied by loss of 1 MINPP1 allele, loss of 1 copy, mutation, or low expression of PAPSS2, and most frequently by loss of 1 or 2 copies or low expression of FLJ11218. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732919     DOI: 10.1002/gcc.10311

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

1.  Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage.

Authors:  Jianfeng Xu; Carl D Langefeld; S Lilly Zheng; Elizabeth M Gillanders; Bao-Li Chang; Sarah D Isaacs; Adrienne H Williams; Kathy E Wiley; Latchezar Dimitrov; Deborah A Meyers; Patrick C Walsh; Jeffrey M Trent; William B Isaacs
Journal:  Hum Genet       Date:  2004-06-05       Impact factor: 4.132

2.  Cytogenetically balanced translocations are associated with focal copy number alterations.

Authors:  Spencer K Watson; Ronald J deLeeuw; Doug E Horsman; Jeremy A Squire; Wan L Lam
Journal:  Hum Genet       Date:  2006-10-19       Impact factor: 4.132

3.  Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

Authors:  Myles C Hodgson; Long-jiang Shao; Anna Frolov; Rile Li; Leif E Peterson; Gustavo Ayala; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

4.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

5.  EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.

Authors:  Yuexing Zhang; Douglas Linn; Zhenqiu Liu; Jonathan Melamed; Fabio Tavora; Charles Y Young; Angelika M Burger; Anne W Hamburger
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

6.  Effects of Muclin (Dmbt1) deficiency on the gastrointestinal system.

Authors:  Robert C De Lisle; Weihong Xu; Bruce A Roe; Donna Ziemer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-01-17       Impact factor: 4.052

7.  RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.

Authors:  Todd M Morgan; Tiffany E M Pitts; Ted S Gross; Sandra L Poliachik; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

8.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Authors:  A H M Reid; G Attard; L Ambroisine; G Fisher; G Kovacs; D Brewer; J Clark; P Flohr; S Edwards; D M Berney; C S Foster; A Fletcher; W L Gerald; H Møller; V E Reuter; P T Scardino; J Cuzick; J S de Bono; C S Cooper
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

9.  Recurring Translocations in Barrett's Esophageal Adenocarcinoma.

Authors:  Manisha Bajpai; Anshuman Panda; Kristen Birudaraju; James Van Gurp; Amitabh Chak; Kiron M Das; Parisa Javidian; Hana Aviv
Journal:  Front Genet       Date:  2021-06-09       Impact factor: 4.599

10.  Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.

Authors:  Joern Kamradt; Volker Jung; Kerstin Wahrheit; Laura Tolosi; Joerg Rahnenfuehrer; Martin Schilling; Robert Walker; Sean Davis; Michael Stoeckle; Paul Meltzer; Bernd Wullich
Journal:  PLoS One       Date:  2007-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.